Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $4 from $7 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says recurring revenue strength offset weakness in the company’s instrument segment. It believes Cytek’s visibility remains limited.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences Earnings Call Reveals Mixed Outlook
- Cytek Biosciences: Q2 2025 Financial Performance Overview
- Cytek Biosciences Faces Market Challenges and Uncertain Growth Prospects Leading to Hold Rating
- Cytek Biosciences reports Q2 EPS (4c), consensus (1c)
- Cytek Biosciences narrows FY25 revenue view to $196M-$200M from $196M-$210M